Form 8-K - Current report:
SEC Accession No. 0001558370-22-007951
Filing Date
2022-05-10
Accepted
2022-05-10 06:32:05
Documents
14
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imrx-20220510x8k.htm   iXBRL 8-K 38568
2 EX-99.1 imrx-20220510xex99d1.htm EX-99.1 181326
3 GRAPHIC imrx-20220510xex99d1002.jpg GRAPHIC 6512
  Complete submission text file 0001558370-22-007951.txt   366173

Data Files

Seq Description Document Type Size
4 EX-101.SCH imrx-20220510.xsd EX-101.SCH 3163
5 EX-101.LAB imrx-20220510_lab.xml EX-101.LAB 16585
6 EX-101.PRE imrx-20220510_pre.xml EX-101.PRE 10467
8 EXTRACTED XBRL INSTANCE DOCUMENT imrx-20220510x8k_htm.xml XML 5043
Mailing Address 245 MAIN STREET, SECOND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, SECOND FLOOR CAMBRIDGE MA 02142 617-500-8080
Immuneering Corp (Filer) CIK: 0001790340 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40675 | Film No.: 22907250
SIC: 2834 Pharmaceutical Preparations